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NUEDEXTA (dextromethorphan/quinidine) is the only FDA and EMA approved PBA 
treatment. The primary objective of this analysis is to evaluate healthcare utili-
zation and costs in PBA patients before and after dextromethorphan/quinidine 
treatment. For this analysis type of service unit utilized and overall utilization 
are both functions of cost. METHODS: Retrospective analysis using anonymized 
patient level data from a large national health insurer. Claims data (both commercial 
and Medicare) were assessed for each eligible patient, for an observation period 
including the 12 months before (baseline) and 12 months after (follow-up) the Index 
Date, defined as the first prescription fill date for dextromethorphan/quinidine. 
Eligibility requirements were an Index Date between January 1, 2007 through August 
31, 2013, and continuous insurance eligibility for the entire 24 month observation 
period . RESULTS: A cohort of 1245 patients treated with dextromethorphan/qui-
nidine was identified; 488 of whom met eligibility requirements. Mean healthcare 
costs, primarily driven by utilization, were reduced in the 12 months following 
dextromethorphan/quinidine use compared with the 12 months pretreatment, 
including reduction of inpatient costs (27%), emergency room visits (19%), stroke-
related postcare (73%) and ancillary costs (2%). Pre-index costs were not reflective 
of costs related to acute stroke treatment in stroke patients, as no patient had a 
stroke during the 12-month pre-index (baseline) period. Despite the added prescrip-
tion cost of dextromethorphan/quinidine, the overall weighted mean cost reduc-
tion was 5%. CONCLUSIONS: Patients treated with dextromethorphan/quinidine 
(NUEDEXTA) showed a decrease in healthcare utilization and costs compared to 
the pre-index period.
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OBJECTIVES: To evaluate multiple sclerosis (MS)-related health care resource 
utilization and costs prior to and after initiating natalizumab in 
Germany. METHODS: A retrospective claims database analysis was conducted 
using the Health Risk Institute research database to identify MS patients ini-
tiating natalizumab (index date) between 1/1/2009 and 12/31/2012. Patients 
had 24 months of continuous enrollment (12 months before [pre-period] and 
12 months after [post-period] the index date) and at least one natalizumab pre-
scription in the 4th quarter after the index date. Furthermore, patients with and 
without other disease-modifying treatment (DMT) during the pre-period were 
examined. Patient characteristics, MS-related inpatient stays, and corticos-
teroid use were compared in both periods using paired statistical tests, where 
appropriate. RESULTS: The study included 193 patients, mean age 37.1 years 
(standard deviation 10.2), 64.8% female. The majority (75.1%) used a DMT dur-
ing the pre-period. After initiating natalizumab, there was a significant reduc-
tion in the percentage of patients with MS-related inpatient stays (49.7% 
versus 14.0%, P< 0.001), MS-related inpatient costs (mean € 3,759 versus 
€ 815, P< 0.001), and length of stay (mean 7.0 days versus 2.7 days, P< 0.001) 
compared to the pre-period. In patients without pre-period DMTs, there was a 
significant reduction in the percentage of patients with MS-related inpatient stays 
(–77.3% P< 0.001) and costs (-€ 3052.0; P< 0.001) and patients with DMTs in the pre-
period showed similar significant reductions (–70.2% and –€ 2908.2, respectively, 
P< 0.001 for both). Compared to the pre-period, there were significant reductions 
in corticosteroid use for all natalizumab initiators (–62.3%, P< 0.001), which cor-
responded to a mean corticosteroid cost-per-patient reduction of –€ 290.75 across 
all natalizumab users (P< 0.001). CONCLUSIONS: In Germany, the initiation of 
natalizumab was associated with significant decreases in MS-related inpatient 
stays, and corticosteroid use with corresponding decreases in the average length of 
stay and costs among natalizumab users with and without DMTs in the prior year.
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OBJECTIVES: sIBM is a progressive idiopathic inflammatory myopathy characterized 
by atrophy and weakness of proximal and distal muscle groups; knee extensors and 
wrist/finger flexors and dysphagic processes are frequently involved. Progressive 
weakness results in loss of independence and need for assistive devices and sup-
portive care. The progressive nature of sIBM leads to increasing medical expenses, 
many of which are not covered by third-party payers, making quantification difficult 
using existing databases. SMART-sIBM, a self-report tool, was developed to better 
characterize out-of-pocket expenses and non-reimbursable items not captured by 
health care systems. METHODS: SMART-sIBM was developed based on in-depth 
interview data from 20 sIBM patients, review of existing resource-use measures, 
and input from clinical experts (n= 9). SMART-sIBM captures resource utilization 
and costs of sIBM over a 6-month, retrospective recall period, including out-of-
pocket costs and third-party payer expenses. A cross-sectional study (n= 102 sIBM 
patients) was conducted in the US to gather preliminary resource utilization and 
patient financial data. Draft versions were reviewed by clinical experts and patients 
independently, and were refined before use in the cross-sectional study. RESULTS: 
Patients had a mean age of 66 years, disease duration of 1-18 years, and varied physi-
cal limitations. All patients reported need for frequent health care visits, and 80% 
indicated need for house/vehicle modifications and purchase of assistive equipment 
to accommodate sIBM-related disabilities. Nearly one-third of patients required 
paid help with household tasks, while more than one-half relied on help from 
unpaid caregivers (e.g., spouse, friend). Nearly half (45%) reported changes in job 
status because of sIBM-related functional limitations. CONCLUSIONS: Results of 
comparison to evaluate the efficacy and safety, with the study of Jiao and cols., an 
hypothetical cohort were placed in accordance with this efficacy and the Hoehn 
and Yahr states, an analysis of incremental cost-effectiveness ratio (ICER) was 
performed. We used a markov model to estimate the CE and performed sensitivity 
analyses and varying disease progression parameters and costs. The outcome of 
effectiveness was life years gained. RESULTS: For patients with early PD in mono-
therapy, treatment with levodopa had lower costs and more effectiveness than 
pramipexole, rasagiline and selegiline treatments. With a time horizon of 5 years, 
levodopa was 5.04 life years gained and cost $236,750.52, the cost of selegiline 
was $247,094.21 with 4.1 life years gained, pramipexol had a cost of $247,420.46 
with 4.1 life years gained and finally rasagilina $254,006.56 with 3.17 life years 
gained, all values of ICER were less than one GDP per capital. This results showed 
that levodopa was the dominant alternative. The sensitivity analyses confirm the 
results. CONCLUSIONS: Findings of this study indicate that levodopa provides 
the major effectiveness and the lower cost compared to pramipexole, rasagiline 
and selegiline as first treatment option in patients with early Parkinson disease 
(measured by UPDRS) in monotherapy.
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OBJECTIVES: Lisdexamfetamine dimesylate (LDX) demonstrated efficacy in terms 
of reduced binge eating days per week in adults (18-55 years old) with binge eating 
disorder (BED) in 2 randomized control trials (RCTs). This study examined the cost-
effectiveness of LDX compared to placebo for the treatment of adult BED patients 
in the United States (U.S.). METHODS: A decision-analytic Markov cohort model 
comparing LDX to placebo was developed using 1-week cycles and a 52-week time 
horizon. Based upon the 5th Edition of the Diagnostic and Statistical Manual of 
Mental Disorders criteria of BED, the model comprised the following health states: 
non-symptomatic BED, sub-threshold BED, mild BED, moderate BED and severe 
and extreme BED. Model parameter estimates including transition probabilities, 
utility values and resource utilization were obtained from RCTs, a survey, and lit-
erature. All cost data were inflated to 2013. The primary outcome was incremental 
cost-effectiveness ratio (ICER). The base case analysis assumed a 12-week course 
of treatment, based upon RCTs’ treatment duration. RESULTS: Patients on LDX 
therapy gained 0.0064 quality-adjusted life years (QALY) compared to patients on 
the NPT arm, while the average total cost was $175 higher for LDX therapy. LDX 
therapy yielded the ICER of $27,512 per QALY gained vs placebo and was shown to 
be cost-effective given a willingness-to-pay threshold of $50,000. CONCLUSIONS: 
Treatment of BED with LDX showed an increase in QALYs at an acceptable cost and 
considered cost-effective at the commonly used willingness-to-pay thresholds in 
the U.S. There is a need to generate additional scientific evidence supporting long-
term benefits of LDX therapy for BED.
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OBJECTIVES: To evaluate the cost-effectiveness of glatiramer acetate (COPAXONE®) 
for relapsing-remitting multiple sclerosis (RRMS) compared to interferons-β (IFNs) 
in scenarios with and without routine testing for the presence of neutralizing anti-
bodies (NAbs) in people receiving IFNs. NAbs reduce the therapeutic benefits of 
interferons-β (IFNs). Glatiramer acetate does not develop NAbs. METHODS: The 
impact of NAb testing was evaluated using a Markov model previously developed 
for the Netherlands. The model followed patients over 50 years through 21 health 
states: Expanded Disability Status Scale (EDSS) 0-9 for patients with RRMS and 
secondary progressive multiple sclerosis, respectively, and death (EDSS 10). Baseline 
demographics, transition probabilities, treatment-specific relative risks, and utility 
values were obtained from published literature. Health resource use was based on 
the products’ Summary of Product Characteristics and treatment guidelines. 2014 
unit costs were based on national tariffs and published data from the Netherlands. 
The analysis was conducted from the societal perspective. RESULTS: In the scenario 
without routine NAb testing total treatment costs of glatiramer acetate were lower 
versus most IFNs. It also resulted in higher number of quality-adjusted life-years 
compared to all IFNs as some IFN patients received ineffective treatment. In the 
scenario with routine NAb testing total treatment costs of all IFNs were higher 
than in the other scenario and higher than glatiramer acetate due to switching to 
more expensive treatments than first-line injectables. In both scenarios glatiramer 
acetate was dominant against most IFNs. CONCLUSIONS: In both scenarios where 
NAb testing is routine practice or not, glatiramer acetate is less costly and more 
effective versus interferon-β -1a 44mcg, 30mcg, and 22mcg for RRMS.
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OBJECTIVES: Pseudobulbar affect (PBA) is an underdiagnosed condition character-
ized by sudden, involuntary episodes of crying and/or laughing in patients with 
traumatic brain injury or certain neurologic diseases, including multiple sclerosis, 
amyotrophic lateral sclerosis, stroke, Alzheimer’s disease, and others. Studies sug-
gest that PBA symptoms are associated with added healthcare utilization and costs. 
